APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Entecavir Tablets

Compare research editions
View pricing & licenses

Selected research

Industry Research

Entecavir Tablets Industry Research Report 2026

28 December 2025130 pages

Choose your research edition.

Industry ResearchEntecavir Tablets Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Entecavir Tablets Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Entecavir Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Entecavir Tablets Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Entecavir Tablets Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Entecavir Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Entecavir Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Entecavir Tablets is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Entecavir Tablets is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Entecavir Tablets include Amneal Pharmaceuticals, Bristol Myers Squibb, Camber Pharmaceuticals, Cipla, Hetero Labs, Sandoz Pharmaceuticals, Sun Pharmaceutical, Teva and Towa Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Entecavir Tablets market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Entecavir Tablets Market by Company

Amneal Pharmaceuticals

Bristol Myers Squibb

Camber Pharmaceuticals

Cipla

Hetero Labs

Sandoz Pharmaceuticals

Sun Pharmaceutical

Teva

Towa Pharmaceutical

Zydus

Beijing Baiao Pharmaceutical

HEC Pharm

Fujian Cosunter pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

YaoPharma

Chia Tai Tianqing Pharmaceutical

Entecavir Tablets Segment by Type

0.5mg per Tablet

1mg per Tablet

Entecavir Tablets Segment by Application

Hospital and Clinic

Pharmacy

Other

Entecavir Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Entecavir Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Entecavir Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Entecavir Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Entecavir Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Entecavir Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Entecavir Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Entecavir Tablets Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Entecavir Tablets Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Entecavir Tablets Sales Market Share by Manufacturers (2021-2026) Table 8. Global Entecavir Tablets Revenue of Manufacturers (2021-2026) Table 9. Global Entecavir Tablets Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Entecavir Tablets Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Entecavir Tablets Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Entecavir Tablets, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Entecavir Tablets, Product Type & Application Table 14. Global Entecavir Tablets Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Entecavir Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Amneal Pharmaceuticals Company Information Table 19. Amneal Pharmaceuticals Business Overview Table 20. Amneal Pharmaceuticals Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Amneal Pharmaceuticals Entecavir Tablets Product Portfolio Table 22. Amneal Pharmaceuticals Recent Developments Table 23. Bristol Myers Squibb Company Information Table 24. Bristol Myers Squibb Business Overview Table 25. Bristol Myers Squibb Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bristol Myers Squibb Entecavir Tablets Product Portfolio Table 27. Bristol Myers Squibb Recent Developments Table 28. Camber Pharmaceuticals Company Information Table 29. Camber Pharmaceuticals Business Overview Table 30. Camber Pharmaceuticals Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Camber Pharmaceuticals Entecavir Tablets Product Portfolio Table 32. Camber Pharmaceuticals Recent Developments Table 33. Cipla Company Information Table 34. Cipla Business Overview Table 35. Cipla Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Cipla Entecavir Tablets Product Portfolio Table 37. Cipla Recent Developments Table 38. Hetero Labs Company Information Table 39. Hetero Labs Business Overview Table 40. Hetero Labs Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Hetero Labs Entecavir Tablets Product Portfolio Table 42. Hetero Labs Recent Developments Table 43. Sandoz Pharmaceuticals Company Information Table 44. Sandoz Pharmaceuticals Business Overview Table 45. Sandoz Pharmaceuticals Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sandoz Pharmaceuticals Entecavir Tablets Product Portfolio Table 47. Sandoz Pharmaceuticals Recent Developments Table 48. Sun Pharmaceutical Company Information Table 49. Sun Pharmaceutical Business Overview Table 50. Sun Pharmaceutical Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sun Pharmaceutical Entecavir Tablets Product Portfolio Table 52. Sun Pharmaceutical Recent Developments Table 53. Teva Company Information Table 54. Teva Business Overview Table 55. Teva Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Teva Entecavir Tablets Product Portfolio Table 57. Teva Recent Developments Table 58. Towa Pharmaceutical Company Information Table 59. Towa Pharmaceutical Business Overview Table 60. Towa Pharmaceutical Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Towa Pharmaceutical Entecavir Tablets Product Portfolio Table 62. Towa Pharmaceutical Recent Developments Table 63. Zydus Company Information Table 64. Zydus Business Overview Table 65. Zydus Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Zydus Entecavir Tablets Product Portfolio Table 67. Zydus Recent Developments Table 68. Beijing Baiao Pharmaceutical Company Information Table 69. Beijing Baiao Pharmaceutical Business Overview Table 70. Beijing Baiao Pharmaceutical Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Beijing Baiao Pharmaceutical Entecavir Tablets Product Portfolio Table 72. Beijing Baiao Pharmaceutical Recent Developments Table 73. HEC Pharm Company Information Table 74. HEC Pharm Business Overview Table 75. HEC Pharm Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. HEC Pharm Entecavir Tablets Product Portfolio Table 77. HEC Pharm Recent Developments Table 78. Fujian Cosunter pharmaceutical Company Information Table 79. Fujian Cosunter pharmaceutical Business Overview Table 80. Fujian Cosunter pharmaceutical Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Fujian Cosunter pharmaceutical Entecavir Tablets Product Portfolio Table 82. Fujian Cosunter pharmaceutical Recent Developments Table 83. Qilu Pharmaceutical Company Information Table 84. Qilu Pharmaceutical Business Overview Table 85. Qilu Pharmaceutical Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Qilu Pharmaceutical Entecavir Tablets Product Portfolio Table 87. Qilu Pharmaceutical Recent Developments Table 88. CSPC Ouyi Pharmaceutical Company Information Table 89. CSPC Ouyi Pharmaceutical Business Overview Table 90. CSPC Ouyi Pharmaceutical Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. CSPC Ouyi Pharmaceutical Entecavir Tablets Product Portfolio Table 92. CSPC Ouyi Pharmaceutical Recent Developments Table 93. YaoPharma Company Information Table 94. YaoPharma Business Overview Table 95. YaoPharma Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. YaoPharma Entecavir Tablets Product Portfolio Table 97. YaoPharma Recent Developments Table 98. Chia Tai Tianqing Pharmaceutical Company Information Table 99. Chia Tai Tianqing Pharmaceutical Business Overview Table 100. Chia Tai Tianqing Pharmaceutical Entecavir Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Chia Tai Tianqing Pharmaceutical Entecavir Tablets Product Portfolio Table 102. Chia Tai Tianqing Pharmaceutical Recent Developments Table 103. Global Entecavir Tablets Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Entecavir Tablets Sales by Region (2021-2026) & (K Units) Table 105. Global Entecavir Tablets Sales Market Share by Region (2021-2026) Table 106. Global Entecavir Tablets Sales by Region (2027-2032) & (K Units) Table 107. Global Entecavir Tablets Sales Market Share by Region (2027-2032) Table 108. Global Entecavir Tablets Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Entecavir Tablets Revenue Market Share by Region (2021-2026) Table 110. Global Entecavir Tablets Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Entecavir Tablets Revenue Market Share by Region (2027-2032) Table 112. North America Entecavir Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Entecavir Tablets Sales by Country (2021-2026) & (K Units) Table 114. North America Entecavir Tablets Sales by Country (2027-2032) & (K Units) Table 115. North America Entecavir Tablets Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Entecavir Tablets Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Entecavir Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Entecavir Tablets Sales by Country (2021-2026) & (K Units) Table 119. Europe Entecavir Tablets Sales by Country (2027-2032) & (K Units) Table 120. Europe Entecavir Tablets Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Entecavir Tablets Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Entecavir Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Entecavir Tablets Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific Entecavir Tablets Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific Entecavir Tablets Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Entecavir Tablets Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Entecavir Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Entecavir Tablets Sales by Country (2021-2026) & (K Units) Table 129. South America Entecavir Tablets Sales by Country (2027-2032) & (K Units) Table 130. South America Entecavir Tablets Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Entecavir Tablets Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Entecavir Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Entecavir Tablets Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Entecavir Tablets Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Entecavir Tablets Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Entecavir Tablets Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Entecavir Tablets Sales by Type (2021-2026) & (K Units) Table 138. Global Entecavir Tablets Sales by Type (2027-2032) & (K Units) Table 139. Global Entecavir Tablets Sales Market Share by Type (2021-2026) Table 140. Global Entecavir Tablets Sales Market Share by Type (2027-2032) Table 141. Global Entecavir Tablets Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Entecavir Tablets Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Entecavir Tablets Revenue Market Share by Type (2021-2026) Table 144. Global Entecavir Tablets Revenue Market Share by Type (2027-2032) Table 145. Global Entecavir Tablets Price by Type (2021-2026) & (US$/Unit) Table 146. Global Entecavir Tablets Price by Type (2027-2032) & (US$/Unit) Table 147. Global Entecavir Tablets Sales by Application (2021-2026) & (K Units) Table 148. Global Entecavir Tablets Sales by Application (2027-2032) & (K Units) Table 149. Global Entecavir Tablets Sales Market Share by Application (2021-2026) Table 150. Global Entecavir Tablets Sales Market Share by Application (2027-2032) Table 151. Global Entecavir Tablets Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Entecavir Tablets Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Entecavir Tablets Revenue Market Share by Application (2021-2026) Table 154. Global Entecavir Tablets Revenue Market Share by Application (2027-2032) Table 155. Global Entecavir Tablets Price by Application (2021-2026) & (US$/Unit) Table 156. Global Entecavir Tablets Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Entecavir Tablets Distributors List Table 160. Entecavir Tablets Customers List Table 161. Entecavir Tablets Industry Trends Table 162. Entecavir Tablets Industry Drivers Table 163. Entecavir Tablets Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Entecavir Tablets Product Image Figure 5. Global Entecavir Tablets Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Entecavir Tablets Market Size (2021-2032) & (US$ Million) Figure 7. Global Entecavir Tablets Sales (2021-2032) & (K Units) Figure 8. Global Entecavir Tablets Average Price (US$/Unit) & (2021-2032) Figure 9. 0.5mg per Tablet Product Image Figure 10. 1mg per Tablet Product Image Figure 11. Hospital and Clinic Product Image Figure 12. Pharmacy Product Image Figure 13. Other Product Image Figure 14. Global Entecavir Tablets Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Entecavir Tablets, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Entecavir Tablets Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Entecavir Tablets Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Entecavir Tablets Sales by Region in 2025 Figure 20. Global Entecavir Tablets Revenue by Region in 2025 Figure 21. North America Entecavir Tablets Market Size by Country in 2025 Figure 22. North America Entecavir Tablets Sales Market Share by Country (2021-2032) Figure 23. North America Entecavir Tablets Revenue Market Share by Country (2021-2032) Figure 24. United States Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Entecavir Tablets Market Size by Country in 2025 Figure 28. Europe Entecavir Tablets Sales Market Share by Country (2021-2032) Figure 29. Europe Entecavir Tablets Revenue Market Share by Country (2021-2032) Figure 30. Germany Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Entecavir Tablets Market Size by Country in 2025 Figure 41. Asia Pacific Entecavir Tablets Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Entecavir Tablets Revenue Market Share by Country (2021-2032) Figure 43. China Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Entecavir Tablets Market Size by Country in 2025 Figure 52. South America Entecavir Tablets Sales Market Share by Country (2021-2032) Figure 53. South America Entecavir Tablets Revenue Market Share by Country (2021-2032) Figure 54. Brazil Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Entecavir Tablets Market Size by Country in 2025 Figure 58. Middle East and Africa Entecavir Tablets Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Entecavir Tablets Revenue Market Share by Country (2021-2032) Figure 60. Egypt Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Entecavir Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Entecavir Tablets Sales Market Share by Type (2021-2032) Figure 66. Global Entecavir Tablets Revenue Market Share by Type (2021-2032) Figure 67. Global Entecavir Tablets Price (US$/Unit) by Type (2021-2032) Figure 68. Global Entecavir Tablets Sales Market Share by Application (2021-2032) Figure 69. Global Entecavir Tablets Revenue Market Share by Application (2021-2032) Figure 70. Global Entecavir Tablets Price (US$/Unit) by Application (2021-2032) Figure 71. Entecavir Tablets Value Chain Figure 72. Entecavir Tablets Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Entecavir Tablets Industry Opportunities and Challenges

Scope & coverage.

Types
  • 0.5mg per Tablet
  • 1mg per Tablet
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Amneal Pharmaceuticals
  • Bristol Myers Squibb
  • Camber Pharmaceuticals
  • Cipla
  • Hetero Labs
  • Sandoz Pharmaceuticals
  • Sun Pharmaceutical
  • Teva
  • Towa Pharmaceutical
  • Zydus
  • Beijing Baiao Pharmaceutical
  • HEC Pharm
  • Fujian Cosunter pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • YaoPharma
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Entecavir Tablets Market Size (2021-2032)
  4. 2.2.2 Global Entecavir Tablets Sales (2021-2032)
  5. 2.2.3 Global Entecavir Tablets Market Average Price (2021-2032)
  6. 2.3 Entecavir Tablets by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 0.5mg per Tablet
  9. 2.3.3 1mg per Tablet
  10. 2.4 Entecavir Tablets by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital and Clinic
  13. 2.4.3 Pharmacy
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Entecavir Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Entecavir Tablets Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Entecavir Tablets Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Entecavir Tablets Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Entecavir Tablets Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Entecavir Tablets, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Entecavir Tablets, Product Type & Application
  8. 3.8 Global Manufacturers of Entecavir Tablets, Established Date
  9. 3.9 Global Entecavir Tablets Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Amneal Pharmaceuticals
  2. 4.1.1 Amneal Pharmaceuticals Company Information
  3. 4.1.2 Amneal Pharmaceuticals Business Overview
  4. 4.1.3 Amneal Pharmaceuticals Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Amneal Pharmaceuticals Entecavir Tablets Product Portfolio
  6. 4.1.5 Amneal Pharmaceuticals Recent Developments
  7. 4.2 Bristol Myers Squibb
  8. 4.2.1 Bristol Myers Squibb Company Information
  9. 4.2.2 Bristol Myers Squibb Business Overview
  10. 4.2.3 Bristol Myers Squibb Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bristol Myers Squibb Entecavir Tablets Product Portfolio
  12. 4.2.5 Bristol Myers Squibb Recent Developments
  13. 4.3 Camber Pharmaceuticals
  14. 4.3.1 Camber Pharmaceuticals Company Information
  15. 4.3.2 Camber Pharmaceuticals Business Overview
  16. 4.3.3 Camber Pharmaceuticals Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Camber Pharmaceuticals Entecavir Tablets Product Portfolio
  18. 4.3.5 Camber Pharmaceuticals Recent Developments
  19. 4.4 Cipla
  20. 4.4.1 Cipla Company Information
  21. 4.4.2 Cipla Business Overview
  22. 4.4.3 Cipla Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Cipla Entecavir Tablets Product Portfolio
  24. 4.4.5 Cipla Recent Developments
  25. 4.5 Hetero Labs
  26. 4.5.1 Hetero Labs Company Information
  27. 4.5.2 Hetero Labs Business Overview
  28. 4.5.3 Hetero Labs Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Hetero Labs Entecavir Tablets Product Portfolio
  30. 4.5.5 Hetero Labs Recent Developments
  31. 4.6 Sandoz Pharmaceuticals
  32. 4.6.1 Sandoz Pharmaceuticals Company Information
  33. 4.6.2 Sandoz Pharmaceuticals Business Overview
  34. 4.6.3 Sandoz Pharmaceuticals Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sandoz Pharmaceuticals Entecavir Tablets Product Portfolio
  36. 4.6.5 Sandoz Pharmaceuticals Recent Developments
  37. 4.7 Sun Pharmaceutical
  38. 4.7.1 Sun Pharmaceutical Company Information
  39. 4.7.2 Sun Pharmaceutical Business Overview
  40. 4.7.3 Sun Pharmaceutical Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sun Pharmaceutical Entecavir Tablets Product Portfolio
  42. 4.7.5 Sun Pharmaceutical Recent Developments
  43. 4.8 Teva
  44. 4.8.1 Teva Company Information
  45. 4.8.2 Teva Business Overview
  46. 4.8.3 Teva Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Teva Entecavir Tablets Product Portfolio
  48. 4.8.5 Teva Recent Developments
  49. 4.9 Towa Pharmaceutical
  50. 4.9.1 Towa Pharmaceutical Company Information
  51. 4.9.2 Towa Pharmaceutical Business Overview
  52. 4.9.3 Towa Pharmaceutical Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Towa Pharmaceutical Entecavir Tablets Product Portfolio
  54. 4.9.5 Towa Pharmaceutical Recent Developments
  55. 4.10 Zydus
  56. 4.10.1 Zydus Company Information
  57. 4.10.2 Zydus Business Overview
  58. 4.10.3 Zydus Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Zydus Entecavir Tablets Product Portfolio
  60. 4.10.5 Zydus Recent Developments
  61. 4.11 Beijing Baiao Pharmaceutical
  62. 4.11.1 Beijing Baiao Pharmaceutical Company Information
  63. 4.11.2 Beijing Baiao Pharmaceutical Business Overview
  64. 4.11.3 Beijing Baiao Pharmaceutical Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Beijing Baiao Pharmaceutical Entecavir Tablets Product Portfolio
  66. 4.11.5 Beijing Baiao Pharmaceutical Recent Developments
  67. 4.12 HEC Pharm
  68. 4.12.1 HEC Pharm Company Information
  69. 4.12.2 HEC Pharm Business Overview
  70. 4.12.3 HEC Pharm Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 HEC Pharm Entecavir Tablets Product Portfolio
  72. 4.12.5 HEC Pharm Recent Developments
  73. 4.13 Fujian Cosunter pharmaceutical
  74. 4.13.1 Fujian Cosunter pharmaceutical Company Information
  75. 4.13.2 Fujian Cosunter pharmaceutical Business Overview
  76. 4.13.3 Fujian Cosunter pharmaceutical Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Fujian Cosunter pharmaceutical Entecavir Tablets Product Portfolio
  78. 4.13.5 Fujian Cosunter pharmaceutical Recent Developments
  79. 4.14 Qilu Pharmaceutical
  80. 4.14.1 Qilu Pharmaceutical Company Information
  81. 4.14.2 Qilu Pharmaceutical Business Overview
  82. 4.14.3 Qilu Pharmaceutical Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Qilu Pharmaceutical Entecavir Tablets Product Portfolio
  84. 4.14.5 Qilu Pharmaceutical Recent Developments
  85. 4.15 CSPC Ouyi Pharmaceutical
  86. 4.15.1 CSPC Ouyi Pharmaceutical Company Information
  87. 4.15.2 CSPC Ouyi Pharmaceutical Business Overview
  88. 4.15.3 CSPC Ouyi Pharmaceutical Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 CSPC Ouyi Pharmaceutical Entecavir Tablets Product Portfolio
  90. 4.15.5 CSPC Ouyi Pharmaceutical Recent Developments
  91. 4.16 YaoPharma
  92. 4.16.1 YaoPharma Company Information
  93. 4.16.2 YaoPharma Business Overview
  94. 4.16.3 YaoPharma Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 YaoPharma Entecavir Tablets Product Portfolio
  96. 4.16.5 YaoPharma Recent Developments
  97. 4.17 Chia Tai Tianqing Pharmaceutical
  98. 4.17.1 Chia Tai Tianqing Pharmaceutical Company Information
  99. 4.17.2 Chia Tai Tianqing Pharmaceutical Business Overview
  100. 4.17.3 Chia Tai Tianqing Pharmaceutical Entecavir Tablets Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Chia Tai Tianqing Pharmaceutical Entecavir Tablets Product Portfolio
  102. 4.17.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Entecavir Tablets Market Scenario by Region
  1. 5.1 Global Entecavir Tablets Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Entecavir Tablets Sales by Region: 2021-2032
  3. 5.2.1 Global Entecavir Tablets Sales by Region: 2021-2026
  4. 5.2.2 Global Entecavir Tablets Sales by Region: 2027-2032
  5. 5.3 Global Entecavir Tablets Revenue by Region: 2021-2032
  6. 5.3.1 Global Entecavir Tablets Revenue by Region: 2021-2026
  7. 5.3.2 Global Entecavir Tablets Revenue by Region: 2027-2032
  8. 5.4 North America Entecavir Tablets Market Facts & Figures by Country
  9. 5.4.1 North America Entecavir Tablets Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Entecavir Tablets Sales by Country (2021-2032)
  11. 5.4.3 North America Entecavir Tablets Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Entecavir Tablets Market Facts & Figures by Country
  16. 5.5.1 Europe Entecavir Tablets Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Entecavir Tablets Sales by Country (2021-2032)
  18. 5.5.3 Europe Entecavir Tablets Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Entecavir Tablets Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Entecavir Tablets Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Entecavir Tablets Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Entecavir Tablets Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Entecavir Tablets Market Facts & Figures by Country
  41. 5.7.1 South America Entecavir Tablets Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Entecavir Tablets Sales by Country (2021-2032)
  43. 5.7.3 South America Entecavir Tablets Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Entecavir Tablets Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Entecavir Tablets Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Entecavir Tablets Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Entecavir Tablets Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Entecavir Tablets Sales by Type (2021-2032)
  2. 6.1.1 Global Entecavir Tablets Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Entecavir Tablets Sales Market Share by Type (2021-2032)
  4. 6.2 Global Entecavir Tablets Revenue by Type (2021-2032)
  5. 6.2.1 Global Entecavir Tablets Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Entecavir Tablets Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Entecavir Tablets Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Entecavir Tablets Sales by Application (2021-2032)
  2. 7.1.1 Global Entecavir Tablets Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Entecavir Tablets Sales Market Share by Application (2021-2032)
  4. 7.2 Global Entecavir Tablets Revenue by Application (2021-2032)
  5. 7.2.1 Global Entecavir Tablets Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Entecavir Tablets Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Entecavir Tablets Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Entecavir Tablets Value Chain Analysis
  2. 8.1.1 Entecavir Tablets Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Entecavir Tablets Production Mode & Process
  5. 8.2 Entecavir Tablets Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Entecavir Tablets Distributors
  8. 8.2.3 Entecavir Tablets Customers
9 Global Entecavir Tablets Analyzing Market Dynamics
  1. 9.1 Entecavir Tablets Industry Trends
  2. 9.2 Entecavir Tablets Industry Drivers
  3. 9.3 Entecavir Tablets Industry Opportunities and Challenges
  4. 9.4 Entecavir Tablets Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst